AU2005262701B2 - Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia - Google Patents

Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia Download PDF

Info

Publication number: AU2005262701B2
Authority: AU; Australia
Prior art keywords: reaction chamber; gram negative; breath condensate; exhaled breath; lipopolysaccharide
Prior art date: 2004-06-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Ceased

Application number

AU2005262701A

Other languages

English (en)

Other versions

AU2005262701A1 (en

Inventor

Jackeline Hernandez

Jeffrey A. Kline

John Albert Watts Jr.

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Charlotte Mecklenburg Hospital

Original Assignee

Charlotte Mecklenburg Hospital

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-06-07

Filing date

2005-05-24

Publication date

2011-12-01

2005-05-24 Application filed by Charlotte Mecklenburg Hospital filed Critical Charlotte Mecklenburg Hospital

2006-01-19 Publication of AU2005262701A1 publication Critical patent/AU2005262701A1/en

2011-12-01 Application granted granted Critical

2011-12-01 Publication of AU2005262701B2 publication Critical patent/AU2005262701B2/en

2012-02-27 Priority to AU2012201120A priority Critical patent/AU2012201120A1/en

2012-02-27 Priority to AU2012201118A priority patent/AU2012201118A1/en

2012-02-27 Priority to AU2012201117A priority patent/AU2012201117A1/en

2012-02-27 Priority to AU2012201119A priority patent/AU2012201119A1/en

2025-05-24 Anticipated expiration legal-status Critical

Status Ceased legal-status Critical Current

Links

239000002158 endotoxin Substances 0.000 title claims abstract description 162
229920006008 lipopolysaccharide Polymers 0.000 title claims abstract description 122
201000001178 Bacterial Pneumonia Diseases 0.000 title abstract description 27
238000000034 method Methods 0.000 claims abstract description 55
238000006243 chemical reaction Methods 0.000 claims description 134
208000027096 gram-negative bacterial infections Diseases 0.000 claims description 34
241000894006 Bacteria Species 0.000 claims description 33
230000008859 change Effects 0.000 claims description 25
239000000463 material Substances 0.000 claims description 25
241000251539 Vertebrata <Metazoa> Species 0.000 claims description 20
239000011159 matrix material Substances 0.000 claims description 20
239000000427 antigen Substances 0.000 claims description 17
239000003153 chemical reaction reagent Substances 0.000 claims description 14
238000012544 monitoring process Methods 0.000 claims description 9
239000000872 buffer Substances 0.000 claims description 7
238000005406 washing Methods 0.000 claims description 5
230000029058 respiratory gaseous exchange Effects 0.000 abstract description 12
238000012360 testing method Methods 0.000 description 29
206010035664 Pneumonia Diseases 0.000 description 25
238000003556 assay Methods 0.000 description 21
102000029749 Microtubule Human genes 0.000 description 20
108091022875 Microtubule Proteins 0.000 description 20
210000004688 microtubule Anatomy 0.000 description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
239000011521 glass Substances 0.000 description 15
239000012530 fluid Substances 0.000 description 14
239000003570 air Substances 0.000 description 13
239000003593 chromogenic compound Substances 0.000 description 13
230000000994 depressogenic effect Effects 0.000 description 13
230000003115 biocidal effect Effects 0.000 description 12
150000003839 salts Chemical class 0.000 description 12
239000002826 coolant Substances 0.000 description 11
208000015181 infectious disease Diseases 0.000 description 11
229920002554 vinyl polymer Polymers 0.000 description 11
238000006703 hydration reaction Methods 0.000 description 10
230000008901 benefit Effects 0.000 description 9
230000036571 hydration Effects 0.000 description 9
230000001580 bacterial effect Effects 0.000 description 8
238000001514 detection method Methods 0.000 description 8
102000004169 proteins and genes Human genes 0.000 description 8
108090000623 proteins and genes Proteins 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 7
102000004190 Enzymes Human genes 0.000 description 7
238000011050 LAL assay Methods 0.000 description 7
239000003708 ampul Substances 0.000 description 7
238000003745 diagnosis Methods 0.000 description 7
-1 disaccharide diphosphate Chemical class 0.000 description 7
229920003023 plastic Polymers 0.000 description 7
239000004033 plastic Substances 0.000 description 7
239000013641 positive control Substances 0.000 description 7
238000002560 therapeutic procedure Methods 0.000 description 7
108090000056 Complement factor B Proteins 0.000 description 6
102000003712 Complement factor B Human genes 0.000 description 6
241000239218 Limulus Species 0.000 description 6
208000032376 Lung infection Diseases 0.000 description 6
230000009471 action Effects 0.000 description 6
108010055222 clotting enzyme Proteins 0.000 description 6
238000004891 communication Methods 0.000 description 6
238000009833 condensation Methods 0.000 description 6
230000005494 condensation Effects 0.000 description 6
238000010438 heat treatment Methods 0.000 description 6
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 6
239000007788 liquid Substances 0.000 description 6
229920000642 polymer Polymers 0.000 description 6
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 5
239000004698 Polyethylene Substances 0.000 description 5
210000004369 blood Anatomy 0.000 description 5
239000008280 blood Substances 0.000 description 5
230000000694 effects Effects 0.000 description 5
229920001971 elastomer Polymers 0.000 description 5
210000004072 lung Anatomy 0.000 description 5
230000004048 modification Effects 0.000 description 5
238000012986 modification Methods 0.000 description 5
230000003287 optical effect Effects 0.000 description 5
229920000573 polyethylene Polymers 0.000 description 5
230000009257 reactivity Effects 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 4
239000003242 anti bacterial agent Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
239000011777 magnesium Chemical class 0.000 description 4
229910052749 magnesium Inorganic materials 0.000 description 4
239000003550 marker Substances 0.000 description 4
150000002894 organic compounds Chemical class 0.000 description 4
230000001681 protective effect Effects 0.000 description 4
210000003296 saliva Anatomy 0.000 description 4
239000000126 substance Substances 0.000 description 4
239000000758 substrate Substances 0.000 description 4
238000009423 ventilation Methods 0.000 description 4
206010053567 Coagulopathies Diseases 0.000 description 3
101000779583 Limulus polyphemus Anti-lipopolysaccharide factor Proteins 0.000 description 3
108010040201 Polymyxins Proteins 0.000 description 3
206010036790 Productive cough Diseases 0.000 description 3
206010037660 Pyrexia Diseases 0.000 description 3
239000002250 absorbent Substances 0.000 description 3
230000002745 absorbent Effects 0.000 description 3
239000012080 ambient air Substances 0.000 description 3
239000012491 analyte Substances 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
238000011203 antimicrobial therapy Methods 0.000 description 3
210000000038 chest Anatomy 0.000 description 3
230000035602 clotting Effects 0.000 description 3
230000034994 death Effects 0.000 description 3
238000013461 design Methods 0.000 description 3
239000000975 dye Substances 0.000 description 3
108010072542 endotoxin binding proteins Proteins 0.000 description 3
238000001879 gelation Methods 0.000 description 3
150000004676 glycans Chemical class 0.000 description 3
238000011534 incubation Methods 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
150000003013 phosphoric acid derivatives Chemical class 0.000 description 3
229920001282 polysaccharide Polymers 0.000 description 3
239000005017 polysaccharide Substances 0.000 description 3
108010048121 pro-clotting enzyme Proteins 0.000 description 3
230000004044 response Effects 0.000 description 3
239000000243 solution Substances 0.000 description 3
241000894007 species Species 0.000 description 3
208000024794 sputum Diseases 0.000 description 3
210000003802 sputum Anatomy 0.000 description 3
229920002498 Beta-glucan Polymers 0.000 description 2
241000606161 Chlamydia Species 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
229920001503 Glucan Polymers 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
102000052508 Lipopolysaccharide-binding protein Human genes 0.000 description 2
108010053632 Lipopolysaccharide-binding protein Proteins 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
230000006978 adaptation Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
102000036639 antigens Human genes 0.000 description 2
108091007433 antigens Proteins 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000000721 bacterilogical effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
238000009640 blood culture Methods 0.000 description 2
210000001124 body fluid Anatomy 0.000 description 2
206010006451 bronchitis Diseases 0.000 description 2
239000001569 carbon dioxide Substances 0.000 description 2
229910002092 carbon dioxide Inorganic materials 0.000 description 2
210000002421 cell wall Anatomy 0.000 description 2
230000015271 coagulation Effects 0.000 description 2
238000005345 coagulation Methods 0.000 description 2
150000001875 compounds Chemical class 0.000 description 2
238000011109 contamination Methods 0.000 description 2
230000007423 decrease Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
201000010099 disease Diseases 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
239000003814 drug Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
230000007893 endotoxin activity Effects 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001125 extrusion Methods 0.000 description 2
239000007850 fluorescent dye Substances 0.000 description 2
229910052731 fluorine Inorganic materials 0.000 description 2
239000011737 fluorine Substances 0.000 description 2
239000011888 foil Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000005484 gravity Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
238000003780 insertion Methods 0.000 description 2
230000037431 insertion Effects 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
206010024378 leukocytosis Diseases 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
210000002445 nipple Anatomy 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
244000144985 peep Species 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
230000035699 permeability Effects 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
239000002510 pyrogen Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
229910052710 silicon Inorganic materials 0.000 description 2
239000010703 silicon Substances 0.000 description 2
239000002002 slurry Substances 0.000 description 2
PODWXQQNRWNDGD-UHFFFAOYSA-L sodium thiosulfate pentahydrate Chemical compound O.O.O.O.O.[Na+].[Na+].[O-]S([S-])(=O)=O PODWXQQNRWNDGD-UHFFFAOYSA-L 0.000 description 2
239000007787 solid Substances 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000000007 visual effect Effects 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
RLOWDGUBFHHFMQ-IRXDYDNUSA-N (2S)-5-(diaminomethylideneamino)-2-[[2-[[(2S)-4-methyl-2-(phenylmethoxycarbonylamino)pentanoyl]amino]acetyl]amino]pentanoic acid Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)O RLOWDGUBFHHFMQ-IRXDYDNUSA-N 0.000 description 1
FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
TYMLOMAKGOJONV-UHFFFAOYSA-N 4-nitroaniline Chemical compound NC1=CC=C([N+]([O-])=O)C=C1 TYMLOMAKGOJONV-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
101710099705 Anti-lipopolysaccharide factor Proteins 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241001529572 Chaceon affinis Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
238000012286 ELISA Assay Methods 0.000 description 1
241000588914 Enterobacter Species 0.000 description 1
241000588722 Escherichia Species 0.000 description 1
235000009161 Espostoa lanata Nutrition 0.000 description 1
240000001624 Espostoa lanata Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
229930186217 Glycolipid Natural products 0.000 description 1
241000606790 Haemophilus Species 0.000 description 1
208000002250 Hematologic Neoplasms Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
238000012773 Laboratory assay Methods 0.000 description 1
241000239220 Limulus polyphemus Species 0.000 description 1
102100035131 Lipopolysaccharide-binding protein Human genes 0.000 description 1
208000019693 Lung disease Diseases 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
208000004221 Multiple Trauma Diseases 0.000 description 1
208000023637 Multiple injury Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000204031 Mycoplasma Species 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
241000588653 Neisseria Species 0.000 description 1
101100109397 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) arg-8 gene Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
229910019142 PO4 Chemical class 0.000 description 1
241000606860 Pasteurella Species 0.000 description 1
241000405070 Percophidae Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
206010038687 Respiratory distress Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
206010053879 Sepsis syndrome Diseases 0.000 description 1
201000005010 Streptococcus pneumonia Diseases 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000009470 Ventilator-Associated Pneumonia Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
230000004913 activation Effects 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
230000001986 anti-endotoxic effect Effects 0.000 description 1
108010009352 antilipopolysaccharide factor (Limulus) Proteins 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
230000000712 assembly Effects 0.000 description 1
238000000429 assembly Methods 0.000 description 1
238000003705 background correction Methods 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
210000000601 blood cell Anatomy 0.000 description 1
238000004820 blood count Methods 0.000 description 1
CNVGTZZIUPDIEV-PMACEKPBSA-N butyl N-[(2S)-1-[[2-[[(2S)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-4-methyl-1-oxopentan-2-yl]carbamate Chemical compound [N+](=O)([O-])C1=CC=C(NC([C@@H](NC(CNC([C@@H](NC(=O)OCCCC)CC(C)C)=O)=O)CCCNC(N)=N)=O)C=C1 CNVGTZZIUPDIEV-PMACEKPBSA-N 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
235000011089 carbon dioxide Nutrition 0.000 description 1
238000010523 cascade reaction Methods 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
239000012916 chromogenic reagent Substances 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
239000000701 coagulant Substances 0.000 description 1
108010045487 coagulogen Proteins 0.000 description 1
238000004737 colorimetric analysis Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000012136 culture method Methods 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000000881 depressing effect Effects 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000001177 diphosphate Substances 0.000 description 1
235000011180 diphosphates Nutrition 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
238000003366 endpoint assay Methods 0.000 description 1
230000005284 excitation Effects 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
239000004744 fabric Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
229920005570 flexible polymer Polymers 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
239000008103 glucose Substances 0.000 description 1
230000003862 health status Effects 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000012678 infectious agent Substances 0.000 description 1
230000003993 interaction Effects 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
150000004668 long chain fatty acids Chemical class 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000005399 mechanical ventilation Methods 0.000 description 1
238000002483 medication Methods 0.000 description 1
239000000155 melt Substances 0.000 description 1
WVJKHCGMRZGIJH-UHFFFAOYSA-N methanetriamine Chemical compound NC(N)N WVJKHCGMRZGIJH-UHFFFAOYSA-N 0.000 description 1
244000005700 microbiome Species 0.000 description 1
238000007431 microscopic evaluation Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
VBEGHXKAFSLLGE-UHFFFAOYSA-N n-phenylnitramide Chemical compound [O-][N+](=O)NC1=CC=CC=C1 VBEGHXKAFSLLGE-UHFFFAOYSA-N 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
230000008816 organ damage Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000000149 penetrating effect Effects 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical class [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Chemical class 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920006389 polyphenyl polymer Polymers 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
230000008092 positive effect Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
208000008128 pulmonary tuberculosis Diseases 0.000 description 1
238000011046 pyrogen test Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
238000002601 radiography Methods 0.000 description 1
230000035484 reaction time Effects 0.000 description 1
230000007115 recruitment Effects 0.000 description 1
238000005057 refrigeration Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000009420 retrofitting Methods 0.000 description 1
238000007789 sealing Methods 0.000 description 1
238000012764 semi-quantitative analysis Methods 0.000 description 1
208000013223 septicemia Diseases 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
238000010998 test method Methods 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
239000012780 transparent material Substances 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000003966 vascular damage Effects 0.000 description 1
230000024883 vasodilation Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000002699 waste material Substances 0.000 description 1
238000005303 weighing Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/0813—Measurement of pulmonary parameters by tracers, e.g. radioactive tracers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/083—Measuring rate of metabolism by using breath test, e.g. measuring rate of oxygen consumption
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/08—Measuring devices for evaluating the respiratory organs
- A61B5/097—Devices for facilitating collection of breath or for directing breath into or through measuring devices
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/41—Detecting, measuring or recording for evaluating the immune or lymphatic systems
- A61B5/412—Detecting or monitoring sepsis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
- C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/579—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving limulus lysate
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- G01N2400/50—Lipopolysaccharides; LPS

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Physics & Mathematics (AREA)
General Health & Medical Sciences (AREA)
Biophysics (AREA)
Pathology (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Animal Behavior & Ethology (AREA)
Medical Informatics (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Surgery (AREA)
Pulmonology (AREA)
Hematology (AREA)
Organic Chemistry (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Physiology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Physics & Mathematics (AREA)
Wood Science & Technology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cell Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Vascular Medicine (AREA)
General Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Emergency Medicine (AREA)
Obesity (AREA)

AU2005262701A 2004-06-07 2005-05-24 Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia Ceased AU2005262701B2 (en)

Priority Applications (4)

Application Number	Priority Date	Filing Date	Title
AU2012201120A AU2012201120A1 (en)	2004-06-07	2012-02-27	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
AU2012201118A AU2012201118A1 (en)	2004-06-07	2012-02-27	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
AU2012201117A AU2012201117A1 (en)	2004-06-07	2012-02-27	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
AU2012201119A AU2012201119A1 (en)	2004-06-07	2012-02-27	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US57764104P	2004-06-07	2004-06-07
US60/577,641		2004-06-07
PCT/US2005/018232 WO2006007180A2 (fr)	2004-06-07	2005-05-24	Utilisation de lipopolysaccharide dans un condensat de respiration exhalee aux fins de diagnostic de la pneumonie a gram negatif

Related Child Applications (4)

Application Number	Title	Priority Date	Filing Date
AU2012201120A Division AU2012201120A1 (en)	2004-06-07	2012-02-27	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
AU2012201118A Division AU2012201118A1 (en)	2004-06-07	2012-02-27	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
AU2012201119A Division AU2012201119A1 (en)	2004-06-07	2012-02-27	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
AU2012201117A Division AU2012201117A1 (en)	2004-06-07	2012-02-27	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia

Publications (2)

Publication Number	Publication Date
AU2005262701A1 AU2005262701A1 (en)	2006-01-19
AU2005262701B2 true AU2005262701B2 (en)	2011-12-01

Family

ID=35784291

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2005262701A Ceased AU2005262701B2 (en)	2004-06-07	2005-05-24	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia

Country Status (8)

Country	Link
EP (1)	EP1761166A4 (fr)
JP (2)	JP4804464B2 (fr)
AU (1)	AU2005262701B2 (fr)
BR (1)	BRPI0511846A (fr)
CA (1)	CA2566804A1 (fr)
IL (5)	IL179137A (fr)
MX (1)	MXPA06014248A (fr)
WO (1)	WO2006007180A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004058125A2 (fr)	2002-12-20	2004-07-15	The Charlotte-Mecklenburg Hospital Authority	Dispositif portatif jetable pour la collecte d'un condensat d'air exhale
US7547285B2 (en)	2003-02-14	2009-06-16	The Charlotte-Mecklenburg Hospital Authority	Device and method for collection of exhaled alveolar breath condensate
US7828741B2 (en)	2002-12-20	2010-11-09	The Charlotte-Mecklenburg Hospital Authority	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
WO2009045163A1 (fr)	2007-10-02	2009-04-09	Anna-Carin Olin	Récupération et mesure de particules exhalées
AU2009256172B2 (en) *	2008-06-04	2015-11-26	Kci Licensing, Inc.	Detecting infection in reduced pressure wound treatment
GB201312635D0 (en)	2013-07-15	2013-08-28	Univ Plymouth	Water testing
US10413216B2 (en) *	2016-02-03	2019-09-17	Quintron Instrument Company, Inc.	Breath testing apparatus
CN106018362B (zh) *	2016-05-16	2018-06-08	江苏国恒检测有限公司	一种检测苦味酸的测定器
CN108871908B9 (zh) *	2018-09-06	2024-07-26	杭州优思达生物技术股份有限公司	生物样本处理装置
US12429483B2 (en) *	2019-08-13	2025-09-30	Respiration Scan Ltd	System and method for determining onset and disease progression
WO2021041571A1 (fr) *	2019-08-26	2021-03-04	Zeteo Tech, Inc.	Diagnostic de la tuberculose et d'autres maladies par l'air expiré
WO2023038582A2 (fr) *	2021-09-10	2023-03-16	National University Of Singapore	Kit de prélèvement de condensat d'air expiré
WO2023041753A1 (fr) *	2021-09-20	2023-03-23	Vosbio, Inc.	Dispositifs, procédés et trousses de capture et de traitement d'échantillons biologiques
WO2024254215A1 (fr) *	2023-06-05	2024-12-12	Charles River Laboratories, Inc.	Facteurs de coagulation d'amibocytes recombinés et leurs utilisations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4349626A (en) *	1980-10-28	1982-09-14	The Monell Chemical Senses Center	Method of detecting Pseudomonas aeruginosa infections utilizing selected ketone and/or sulfur metabolites
US5541057A (en) *	1989-09-18	1996-07-30	Biostar, Inc.	Methods for detection of an analyte
US20040234971A1 (en) *	2001-02-01	2004-11-25	Joany Jackman	Diagnosis of pathogen infections using mass spectral analysis of immune system modulators in post-exposure biological samples

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL59383A (en) *	1980-02-14	1983-03-31	Technion Res & Dev Foundation	Micromethod for the determination of endotoxins with limulus amebocyte lysate
SE9704329D0 (sv) *	1997-11-25	1997-11-25	Siemens Elema Ab	Gasmätare
WO2000035337A2 (fr) *	1998-12-18	2000-06-22	University Of Virginia Patent Foundation	Dispositif et procede de surveillance de l'asthme
JP2002539429A (ja) *	1999-03-09	2002-11-19	オスメテックパブリックリミテッドカンパニー	状態検出方法
AU2001261091A1 (en) *	2000-05-01	2001-11-12	Respiratory Research, Inc.	Method and device for collecting and analyzing exhaled breath

2005
- 2005-05-24 MX MXPA06014248A patent/MXPA06014248A/es active IP Right Grant
- 2005-05-24 BR BRPI0511846-8A patent/BRPI0511846A/pt not_active IP Right Cessation
- 2005-05-24 CA CA002566804A patent/CA2566804A1/fr not_active Abandoned
- 2005-05-24 WO PCT/US2005/018232 patent/WO2006007180A2/fr not_active Ceased
- 2005-05-24 AU AU2005262701A patent/AU2005262701B2/en not_active Ceased
- 2005-05-24 JP JP2007527565A patent/JP4804464B2/ja not_active Expired - Fee Related
- 2005-05-24 EP EP05753778A patent/EP1761166A4/fr not_active Withdrawn
2006
- 2006-11-09 IL IL179137A patent/IL179137A/en not_active IP Right Cessation
2009
- 2009-05-15 JP JP2009118170A patent/JP4852121B2/ja not_active Expired - Fee Related
2012
- 2012-02-19 IL IL218191A patent/IL218191A0/en unknown
- 2012-02-19 IL IL218188A patent/IL218188A0/en unknown
- 2012-02-19 IL IL218189A patent/IL218189A0/en unknown
- 2012-02-19 IL IL218190A patent/IL218190A0/en unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4349626A (en) *	1980-10-28	1982-09-14	The Monell Chemical Senses Center	Method of detecting Pseudomonas aeruginosa infections utilizing selected ketone and/or sulfur metabolites
US5541057A (en) *	1989-09-18	1996-07-30	Biostar, Inc.	Methods for detection of an analyte
US20040234971A1 (en) *	2001-02-01	2004-11-25	Joany Jackman	Diagnosis of pathogen infections using mass spectral analysis of immune system modulators in post-exposure biological samples

Also Published As

Publication number	Publication date
EP1761166A4 (fr)	2009-11-11
WO2006007180A2 (fr)	2006-01-19
EP1761166A2 (fr)	2007-03-14
IL218188A0 (en)	2012-04-30
JP4804464B2 (ja)	2011-11-02
BRPI0511846A (pt)	2008-01-15
JP4852121B2 (ja)	2012-01-11
JP2009186487A (ja)	2009-08-20
CA2566804A1 (fr)	2006-01-19
IL218190A0 (en)	2012-04-30
IL218189A0 (en)	2012-04-30
IL218191A0 (en)	2012-04-30
MXPA06014248A (es)	2007-06-25
IL179137A0 (en)	2007-03-08
IL179137A (en)	2012-07-31
JP2008501976A (ja)	2008-01-24
WO2006007180A3 (fr)	2006-11-30
AU2005262701A1 (en)	2006-01-19

Publication	Publication Date	Title
US7828741B2 (en)	2010-11-09	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
JP4852121B2 (ja)	2012-01-11	呼気凝縮液中のリポ多糖体を利用するグラム陰性菌性肺炎の診断
Torres et al.	2000	Bronchoscopic BAL in the diagnosis of ventilator-associated pneumonia
Garay et al.	1979	A new test showing abnormal net Na+ and K+ fluxes in erythrocytes of essential hypertensive patients
US20090305331A1 (en)	2009-12-10	Kits and methods for determining colon cleanliness
US20130190639A1 (en)	2013-07-25	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
Pomrantz et al.	2007	Comparison of serologic evaluation via agar gel immunodiffusion and fungal culture of tissue for diagnosis of nasal aspergillosis in dogs
Rodrguez de Castro et al.	1994	Quantitative cultures of protected brush specimens and bronchoalveolar lavage in ventilated patients without suspected pneumonia.
Tobin	1987	Diagnosis of pneumonia: techniques and problems
AU2012201120A1 (en)	2012-03-15	Utilizing lipopolysaccharide in exhaled breath condensate to diagnose gram negative pneumonia
Arora et al.	2002	Non-bronchoscopic bronchoalveolar lavage in the microbiological diagnosis of pneumonia in mechanically ventilated patients
Berthold et al.	2009	Use of the lactose-[13C] ureide breath test for diagnosis of small bowel bacterial overgrowth: comparison to the glucose hydrogen breath test
Ku et al.	2016	Ability of device to collect bacteria from cough aerosols generated by adults with cystic fibrosis
Grattan-Smith et al.	1987	Viral supraglottitis
Beg et al.	2019	Community-acquired pneumonia secondary to Legionella pneumophila and Streptococcus pneumoniae: a rare co-infection
Brearley et al.	1985	Endotoxin levels in portal and systemic blood
JP4711846B2 (ja)	2011-06-29	甚急性乳房炎の判定方法
RU2305838C1 (ru)	2007-09-10	Способ прогнозирования возникновения повторных респираторных заболеваний у детей раннего возраста, часто и длительно болеющих орз
Stewart et al.	2009	The problems diagnosing ventilator-associated pneumonia
Ahsan et al.	2022	Frequency and outcome of ventilator associated pneumonia in an intensive care unit of a tertiary care hospital in Dhaka
Dennesen et al.	2001	The development of ventilator-associated pneumonia does not change aspects of mechanical ventilation
Forsah et al.	2024	Bilateral empyema with beta hemolytic group C streptococcus and Streptococcus constellatus co-infection resulting from an esophageal perforation and associated with septic shock, diffuse ST elevation, and new-onset atrial fibrillation
Carvalho et al.	2019	Unusual case of a giant lung abscess initially misdiagnosed and treated as an empyema
RU2324191C2 (ru)	2008-05-10	Способ диагностики дисбактериоза кишечника
Solijon o‘g‘li	2025	TESTING FOR TRACHEAL INFECTIONS IN CHILDREN

Legal Events

Date	Code	Title	Description
2012-03-29	FGA	Letters patent sealed or granted (standard patent)
2014-12-18	MK14	Patent ceased section 143(a) (annual fees not paid) or expired